[go: up one dir, main page]

DK1834635T3 - Stabile nanokapselsystemer til administrtion af aktive molekyler - Google Patents

Stabile nanokapselsystemer til administrtion af aktive molekyler

Info

Publication number
DK1834635T3
DK1834635T3 DK06380048.6T DK06380048T DK1834635T3 DK 1834635 T3 DK1834635 T3 DK 1834635T3 DK 06380048 T DK06380048 T DK 06380048T DK 1834635 T3 DK1834635 T3 DK 1834635T3
Authority
DK
Denmark
Prior art keywords
administration
active molecules
stable
nanocapsule systems
stable nanocapsule
Prior art date
Application number
DK06380048.6T
Other languages
English (en)
Inventor
Rez Luque Silvia Sua
Ferna Ndez M Alonso
Pena Ana Isabel Vila
Original Assignee
Advancell Advanced In Vitro Cell Technologies S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advancell Advanced In Vitro Cell Technologies S A filed Critical Advancell Advanced In Vitro Cell Technologies S A
Application granted granted Critical
Publication of DK1834635T3 publication Critical patent/DK1834635T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK06380048.6T 2006-03-13 2006-03-13 Stabile nanokapselsystemer til administrtion af aktive molekyler DK1834635T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06380048A EP1834635B1 (en) 2006-03-13 2006-03-13 Stable nanocapsule systems for the administration of active molecules

Publications (1)

Publication Number Publication Date
DK1834635T3 true DK1834635T3 (da) 2011-10-24

Family

ID=36743270

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06380048.6T DK1834635T3 (da) 2006-03-13 2006-03-13 Stabile nanokapselsystemer til administrtion af aktive molekyler

Country Status (17)

Country Link
US (1) US20090074824A1 (da)
EP (1) EP1834635B1 (da)
JP (1) JP5222739B2 (da)
KR (1) KR20080102303A (da)
CN (1) CN101426479B (da)
AR (1) AR059829A1 (da)
AT (1) ATE515260T1 (da)
AU (1) AU2007224471B2 (da)
BR (1) BRPI0709594A2 (da)
CA (1) CA2646338A1 (da)
DK (1) DK1834635T3 (da)
ES (1) ES2369244T3 (da)
IL (1) IL194005A0 (da)
PE (1) PE20080141A1 (da)
PL (1) PL1834635T3 (da)
PT (1) PT1834635E (da)
WO (1) WO2007104732A2 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119780B2 (en) 2006-06-02 2012-02-21 Synedgen, Inc. Chitosan-derivative compounds and methods of controlling microbial populations
US20080248508A1 (en) * 2006-08-17 2008-10-09 Shenda Baker Methods of making a chitosan product having an ultra-low endotoxin concentration and the ultra-low endotoxin chitosan product derived therefrom and method of accurately determining inflammatory and anti-inflammatory cellular response to such materials
JP5429642B2 (ja) * 2007-06-12 2014-02-26 アレン，クリスティン 薬剤の局所導出を対象とした注射可能なポリマー／脂質ブレンド
EP2601935A1 (en) 2007-09-25 2013-06-12 Solubest Ltd. Compositions comprising lipophilic active compounds and method for their preparation
EP2042166A1 (en) * 2007-09-25 2009-04-01 The Jordanian Pharmaceutical Manufacturing Co. Nanocapsules for oral delivery of proteins
KR101199580B1 (ko) * 2008-08-06 2013-11-27 (주)에델프라우 국소 투여용 나노에멀젼
BRPI0805854A2 (pt) 2008-10-10 2010-08-24 Biolab Sanus Farmaceutica Ltda sistema nanoparticulado, processo de preparaÇço do mesmo, uso do mesmo, composiÇço fotoproterora, processo de preparaÇço da mesma, mÉtodo de prevenÇço de doenÇas e distérbios da pele
TWI328565B (en) * 2008-12-19 2010-08-11 Taiwan Textile Res Inst Dispersions of conductive carbon materials and methods for preparing the same
RU2537181C2 (ru) 2009-03-12 2014-12-27 Нордик Байосайенс А/С Лечение диабета и метаболического синдрома
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
EP2266546A1 (en) * 2009-06-08 2010-12-29 Advancell Advanced in Vitro Cell Technologies,S.A. Process for the preparation of colloidal systems for the delivery of active compounds
EP2364600A1 (en) * 2010-02-18 2011-09-14 Nestec S.A. Liquid-filled chitosan-anionic liposoluble capsule dispsersions
BRPI1002601E2 (pt) * 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos
JP6189749B2 (ja) * 2010-06-23 2017-08-30 ブライトサイド イノベーションズ，インコーポレイティド レシチン担体小胞とその作製方法
JP2013543886A (ja) * 2010-11-26 2013-12-09 ユニバーシティ・オブ・ザ・ウィットウォータースランド・ヨハネスブルグ 医薬投与形態としてのポリマー−脂質ナノ粒子のポリマーマトリックス
US9801829B2 (en) * 2011-04-29 2017-10-31 University Of Florida Research Foundation, Inc. Methods and systems of making nanostructures
DE102011076149A1 (de) * 2011-05-19 2012-11-22 Rovi Cosmetics International Gmbh Ladungsgeber für ein vesikuläres Trägersystem eines UV-Schutzmittels für die Haut oder die Haare
ES2366255B2 (es) * 2011-06-27 2012-08-08 Universidade De Santiago De Compostela Nanocomposiciones sacarídicas para la liberación de vacunas.
BR112014010701A2 (pt) 2011-11-02 2020-06-23 Keybioscience Ag Uso de um peptídeo
EP3095484B1 (en) 2011-11-02 2018-05-02 KeyBioscience AG Calcitonin mimetics for treating diseases and disorders
BR112014011733A2 (pt) * 2011-11-15 2017-05-09 Allergan Inc suspensões autoclaváveis da forma 2 de ciclosporina a
US8968790B2 (en) 2011-12-09 2015-03-03 Shaker A. Mousa Nanoformulation of vitamin D derivatives and/or vitamin D metabolites
EP2625966A1 (en) 2012-02-13 2013-08-14 Bionanoplus, S.L. Nanoparticles comprising a vegetable hydrophobic protein and a water miscible non-volatile organic solvent and uses thereof
CN105026030B (zh) * 2012-12-21 2017-04-12 博莱科瑞士股份有限公司 充气微泡
CA2926797A1 (en) 2013-10-14 2015-04-23 Nanosphere Health Sciences, Llc Nanoparticle compositions and methods as carriers of nutraceutical factors across cell membranes and biological barriers
SI3068796T1 (en) 2013-11-14 2018-05-31 Keybioscience Ag Calcitonin mimetics for the treatment of diseases and disorders
CN104117066B (zh) 2014-07-16 2016-03-02 陈凌 外敷用抗甲状腺软膏的制备方法
CA2970917C (en) * 2014-12-15 2019-09-17 Nanosphere Health Sciences, Llc Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of nsaids
GB201500263D0 (en) 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
WO2016144376A1 (en) 2015-03-10 2016-09-15 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
PL229276B1 (pl) * 2015-07-17 2018-06-29 Univ Jagiellonski Nanokapsuła do przenoszenia związku lipofilowego i sposób jej wytwarzania
US10525012B2 (en) * 2015-08-11 2020-01-07 Eyesiu Medicines B.V. Pegylated lipid nanoparticle with bioactive lipophilic compound
US10765639B2 (en) * 2016-03-25 2020-09-08 Adisseo France S.A.S. Nanocapsules, methods of manufacture and uses thereof
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
CN109316602A (zh) * 2018-11-13 2019-02-12 西安力邦医药科技有限责任公司 一种长效镇痛并促进伤口愈合的复方缓释递药系统的组方与应用
CA3119037A1 (en) 2018-12-11 2020-06-18 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
KR102384808B1 (ko) * 2018-12-20 2022-04-08 주식회사 스킨메드 키토산으로 코팅된 나노 캡슐 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101241A (en) * 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
EP0570829B1 (de) * 1992-05-18 2001-04-25 CicloMulsion AG Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur intravenösen Applikation sowie Verfahren zu ihrer Herstellung
US20030224022A1 (en) * 1993-01-19 2003-12-04 Amos Nussinovitch Hydrocolloid cellular solid matrices
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
ES2093562B1 (es) * 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6649192B2 (en) * 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
JP3441665B2 (ja) * 1999-02-04 2003-09-02 株式会社資生堂 （２−置換オキシフェニル）アルカンアミド誘導体及び養毛剤、皮膚外用剤
EP1190702A1 (en) * 2000-09-22 2002-03-27 Ciba SC Holding AG Chitosan emulsion formulation
EP1243323B1 (de) * 2001-03-22 2005-01-05 Cognis Iberia, S.L. Nanokapseln
ATE468107T1 (de) * 2001-11-01 2010-06-15 Yissum Res Dev Co Verfahren und zusammensetzung zur behandlung von trockenen augen

Also Published As

Publication number Publication date
PL1834635T3 (pl) 2012-01-31
IL194005A0 (en) 2011-08-01
CA2646338A1 (en) 2007-09-20
PE20080141A1 (es) 2008-03-04
PT1834635E (pt) 2011-10-13
CN101426479B (zh) 2012-10-10
ES2369244T3 (es) 2011-11-28
AU2007224471B2 (en) 2013-05-02
JP5222739B2 (ja) 2013-06-26
CN101426479A (zh) 2009-05-06
WO2007104732A2 (en) 2007-09-20
EP1834635A1 (en) 2007-09-19
WO2007104732A3 (en) 2007-11-08
ATE515260T1 (de) 2011-07-15
JP2009530241A (ja) 2009-08-27
AU2007224471A1 (en) 2007-09-20
KR20080102303A (ko) 2008-11-24
EP1834635B1 (en) 2011-07-06
AR059829A1 (es) 2008-04-30
BRPI0709594A2 (pt) 2011-07-19
US20090074824A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
DK1834635T3 (da) Stabile nanokapselsystemer til administrtion af aktive molekyler
DK1983964T3 (da) Anordning til indgivelse af lægemiddel
DK2959894T3 (da) S1p-receptormodulatorer til behandling af multipel sklerose
DK3851447T3 (da) Fremgangsmåder, forbindelser, sammensætninger og vehikler til administration af 3-amino-1-propansulfonsyre
DK2117521T3 (da) Transdermale indgivelsessystemer omfattende bupivacain
DK2054042T3 (da) Fremgangsmåder til fremstilling af biologisk aktive forbindelser i nanopartikelform
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DE602005001512D1 (de) System zur intravenösen Verabreichung
DK2173407T3 (da) Anordning til indgivelse af lægemiddel
BRPI0821876A2 (pt) Sistemas e métodos para administração de medicação
BRPI0821169A2 (pt) Sistema para estabilização ativa e passiva de uma embarcação, e, métodos para estabilização ativa de uma embarcação e para estabilização passiva de uma embarcação
DK2462116T3 (da) Fremgangsmåde til fremstillingen af farmaceutisk aktive forbindelser
DK2019683T4 (da) Indgivelse af vækstfaktorer til behandling af CNS-lidelser
BRPI0821474A2 (pt) formulação farmacêutica líquida estável
DK2010453T3 (da) Fremgangsmåde til fremstilling af flydende carbonhydrider
DK1947933T3 (da) System til styret udbringning af herbicider
DK2094676T3 (da) Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater
DK1942967T3 (da) Fremgangsmåde til dosering af medikamenter
DK1986622T3 (da) Små-molekyle-modulatorer af Trp-p8-aktivitet
DK2249866T3 (da) Anvendelse af et acetylsalicylsyresalt til behandlingen af virusinfektioner
ATE494896T1 (de) Stabile parenterale formulierung mit einem rsv- hemmer einer benzodiazepin-struktur
DK2251019T3 (da) Middel til forebyggelse af alkoholhepatopati
DK2091537T3 (da) Farmaceutiske sammensætninger til behandlingen af kapillær arteriopati
DK1856035T3 (da) Fremgangsmåde til fremstilling af beskyttelse amidiner
DK2060578T3 (da) Fremgangsmåde til fremstilling af optisk aktiv aminophosphinylsmørsyre